Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study - PubMed
6 hours ago
- #Durvalumab
- #Non-Small Cell Lung Cancer
- #Interstitial Lung Disease
- ILD occurred in 75% of patients treated with chemoradiotherapy followed by durvalumab, with a median onset of 44 days.
- Higher radiation exposure (V20 ≥25%, V5 ≥median) and pre-existing grade 1 ILD were associated with increased risk of grade ≥2 ILD.
- ILD management often involved durvalumab discontinuation (31.6%), interruption (29.0%), or corticosteroids (43.9%), highlighting the need for risk minimization strategies.